QS-21 and IL-12 as an adjuvant combination
US7374751B1 · kind B1 · utility
9Cited by
7References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 21, 2001 |
| Grant date | May 20, 2008 |
| Priority date | — |
| Expiry date | Feb 23, 2023 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These compositions elicit functional cell-mediated and humoral immune responses against at least one antigen. Methods of using the disclosed compositions are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.